1. Efficacy of ruxolitinib in acute lymphoblastic leukemia: A systematic review.
- Author
-
Kołodrubiec, Julia, Kozłowska, Marta, Irga-Jaworska, Ninela, Sędek, Łukasz, Pastorczak, Agata, Trelińska, Joanna, and Młynarski, Wojciech
- Subjects
- *
LYMPHOBLASTIC leukemia , *ACUTE leukemia , *JAK-STAT pathway , *RUXOLITINIB , *GENE expression profiling - Abstract
Philadelphia-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk molecular subtype with a gene expression profile similar to Philadelphia-positive ALL, but not harboring the BCR-ABL1 gene fusion. We aimed to investigate the efficacy of target therapy with the Janus kinase inhibitor, ruxolitinib, in patients with Ph-like ALL and molecular signature of JAK-STAT signaling pathway. A systematic search of the literature was performed to identify reports concerning administration of ruxolitinib in Ph-like ALL patients. Additionally, Polish Pediatric ALL registries were searched for patients with Ph-like ALL treated with ruxolitinib. Extracted information included epidemiological background, somatic aberrations, treatment response, and patient outcome. After PubMed database search, twelve patients were identified, and one was identified in the Polish Pediatric ALL registry. In nine patients gene fusions affecting JAK2 (n = 7) and EPOR (n = 2) were detected. Surface overexpression of CRLF2 and IKZF1 deletions were observed in two and three patients, respectively. Induction failure occurred in all the patients. Therapy with ruxolitinib led to complete (n = 7) and partial (n = 2) remission, in three individuals no information was found. Based on the limited number of studies describing the efficacy of ruxolitinib as an additional compound administrated with standard ALL therapy, we conclude that this approach can be considered in patients with aberrations activating JAK-STAT pathway. • Patients with ALL with JAK-STAT molecular signature treated by ruxolitinib. • Ruxolitinib therapy in case of JAK-STAT signature in ALL patients. • JAK inhibitors introduced to the therapy in case of ALL patients with JAK-STAT signature. • Targetable treatment with ruxolitinib in ALL patients with JAK-STAT molecular signature. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF